Citations

Clear

1053 citation(s) found for "Andre, F".

Surface Roughness of Titanium Orthopedic Implants Alters the Biological Phenotype of Human Mesenchymal Stromal Cells
Trousdale, William H. , Thaler, Roman , Xu, Wei , Denbeigh, Janet M. , Nair, Asha, Kocher, Jean‐Pierre , Dudakovic, Amel , Berry, Daniel J., Cohen, Robert C., Lewallen, David G. , Wijnen, André J. van , Berry, Daniel J. , Lewallen, Eric A. , Xu, Wei , van Wijnen, Andre J , Berry, Daniel J , Yao, Jie , Berry, Daniel J., Abdel, Matthew P.

Mayo Clinic

Tissue Engineering Part A | May 12, 2021 | Volume: 27 | Issue: 23-24 | Pages: 1503-1516

10.1089/ten.tea.2020.0369 | PMID 33975459 Get It

Evidence-Based Health Informatics as the Foundation for the COVID-19 Response: A Joint Call for Action
Kushniruk, André, Georgiou, Andrew , Petersen, Carolyn , Ronquillo, Charlene , Paton, Chris , Nøhr, Christian , Skiba, Diane J., Huesing, Elaine, Gabarrón, Elia , Magrabi, Farah , Peute, Linda , Topaz, Max, Al-Shorbaji, Najeeb , Lacroix, Paulette, Cornet, Ronald , Gogia, Shashi Bhushan , Kobayashi, Shinji , Iyengar, Sriram , Mettler, Tobias , Vimarlund, Vivian , Petersen, Carolyn , Fernández-Luque, Luis , Basu, Arindam , Kuziemsky, Craig E. , Alhuwail, Dari , Borycki, Elizabeth M. , Denecke, Kerstin , Marcilly, Romaric , Deserno, Thomas M , Zhu, Xinxin

Mayo Clinic

Methods of Information in Medicine | May 11, 2021 | Volume: 59 | Issue: 06 | Pages: 183-192

10.1055/s-0041-1726414 | PMID 33975375 Get It

Abstract Background As a major public health crisis, the novel coronavirus disease 2019 (COVID-19) pandemic demonstrates the urgent need for safe, effective, and evidence-based implementations of digital health. The urgency stems from the frequent tendency to focus attention on seemingly high promising digital health interventions despite being poorly validated in times of crisis. Aim In this paper, we describe a joint call for action to use and leverage evidence-based health informatics as the foundation for the COVID-19 response and public health interventions. Tangible examples are provided for how the working groups and special interest groups of the International Medical Informatics Association (IMIA) are helping to build an evidence-based response to this crisis. Methods Leaders of working and special interest groups of the IMIA, a total of 26 groups, were contacted via e-mail to provide a summary of the scientific-based efforts taken to combat COVID-19 pandemic and participate in the discussion toward the creation of this manuscript. A total of 13 groups participated in this manuscript. Results Various efforts were exerted by members of IMIA including (1) developing evidence-based guidelines for the design and deployment of digital health solutions during COVID-19; (2) surveying clinical informaticians internationally about key digital solutions deployed to combat COVID-19 and the challenges faced when implementing and using them; and (3) offering necessary resources for clinicians about the use of digital tools in clinical practice, education, and research during COVID-19. Discussion Rigor and evidence need to be taken into consideration when designing, implementing, and using digital tools to combat COVID-19 to avoid delays and unforeseen negative consequences. It is paramount to employ a multidisciplinary approach for the development and implementation of digital health tools that have been rapidly deployed in response to the pandemic bearing in mind human factors, ethics, data privacy, and the diversity of context at the local, national, and international levels. The training and capacity building of front-line workers is crucial and must be linked to a clear strategy for evaluation of ongoing experiences.
Abstract 14765: Exosome Shuttled VEGFR Promotes Angiogenesis in Peripheral Vascular Disease
Arrell, D. Kent , Peterson, Timothy E., Witt, Tyra A. , Nagel, Mary, Li, Jialun , Moran, Steven L. , Shi, Ao , Nagel, Mary, Terzic, André , Behfar, Atta

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.14765 Get It

Introduction: Counteracting the pandemic of peripheral vascular disease necessitates development of proangiogenic treatments. As stem cell benefit has increasingly been associated with paracrine influence on diseased tissue, a purified extracellular vesicle population (PEP) was established to promote tissue regeneration and neovascularization. The mechanistic basis for PEP-induced proangiogenic effects was here probed and validated in two separate in vivo models of vascular ischemia. Hypothesis: PEP drives pro-angiogenic effects though donation of VEGFR. Methods: Nanosight and immunoblotting were utilized to characterize PEP purity and identity. OMICs profiling identified VEGFR as highly prioritized, with downstream signaling was tested in human umbilical vascular endothelial cells using Matrigel assay, qPCR and immunoblotting. In vivo, blood perfusion (Fluorescent imaging - SPY) was quantified in a rodent model of hind-limb ischemia and in a rabbit model of critical ischemic ear, each treated with sham or PEP. Rabbit tissues were next examined by whole transcriptome analysis to assess PEP-induced proangiogenic signaling. Immunohistochemical staining with smooth muscle actin and von Willebrand factor probed de novo blood vessel formation. Results: PEP was characterized by size (mean: 128.6 +/-1 nm) and VEGFR expression. VEGFR knock-down diminished endothelial cell angiogenic activity in vitro, rescued with PEP (5.3x1010+/-109 vesicles/ml) was sufficient enhance total and phosphor-VEGFR expression, along with amplification of downstream VEGFR targets (MAPK, AKT, CXCL8, NOTCH4, MMP9) and enhanced tube formation. In both hind-limb (n=5) and critical ear (n=4) ischemia models, local delivery of PEP to ischemic tissue resulted in restoration of blood perfusion and prioritized proangiogenic signaling in tissue transcriptome pathway analysis, further confirmed by immunohistochemistry. Conclusions: Taken together, our study establishes a new regenerative paradigm documenting exosome-based delivery of VEGFR as a key driver for angiogenesis. This PEP-based platform broadens potential options available for treatment of peripheral vascular disease and may have therapeutic implications in restoration of microvasculature.
Human meniscus allograft augmentation by allogeneic mesenchymal stromal/stem cell injections
Struijk, Caroline , Genechten, Wouter Van , Verdonk, Peter , Krych, Aaron J. , Dietz, Allan B. , Wijnen, André J. van , Saris, Daniël B.F. , Van Genechten, Wouter , van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B

Mayo Clinic

Journal of Orthopaedic Research | May 10, 2021 | Volume: 40 | Issue: 3 | Pages: 712-726

10.1002/jor.25074 | PMID 33969529 Get It

AbstractMeniscus allograft transplantations (MATs) represent established surgical procedures with proven outcomes. Yet, storage as frozen specimens and limited cellular repopulation may impair graft viability. This proof‐of‐concept study tests the feasibility of injecting allogeneic mesenchymal stromal/stem cells (MSCs) in meniscus allograft tissue. We investigated the injectable cell quantity, survival rate, migration, and proliferation ability of MSCs up to 28 days of incubation. In this controlled laboratory study, seven fresh‐frozen human allografts were injected with human allogeneic MSCs. Cells were labeled and histological characteristics were microscopically imaged up to 28 days. Mock‐injected menisci were included as negative controls in each experiment. Toluidine blue staining demonstrated that a 100‐µl volume can be injected while retracting and rotating the inserted needle. Immediately after injection, labeled MSCs were distributed throughout the injection channel and eventually migrated into the surrounding tissues. Histological assessment revealed that MSCs cluster in disc‐like shapes, parallel to the intrinsic lamination of the meniscus and around the vascular network. Quantification showed that more than 60% of cells were present in horizontally injected grafts and more than 30% were observed in vertically injected samples. On Day 14, cells adopted a spindle‐shaped morphology and exhibited proliferative and migratory behaviors. On Day 28, live/dead ratio assessment revealed an approximately 80% cell survival. The study demonstrated the feasibility of injecting doses of MSCs (>0.1 million) in meniscus allograft tissue with active cell proliferation, migration, and robust cell survival.
Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
Perotti, Paola, Loli, Paola , Decoudier, Bénédicte , Lasolle, Hélène , Dušek, Tina , Bourdeau, Isabelle , Baudin, Éric , Bertherat, Jerome Yves, Terzolo, Massimo , Faßnacht, Martin , Libé, Rossella , Lacroix, André , Kaštelan, Darko , Haak, Harm Reinout , Arlt, Wiebke , Bancos, Irina , Quinkler, Marcus , Fragoso, Maria Candida Barisson Villares , Canu, Letizia , Puglisi, Soraya , Kroiß, Matthias , Berchialla, Paola , Beuschlein, Felix , Berruti, Alfredo

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A166-A167

10.1210/jendso/bvab048.336 Get It

Abstract Background: The ESE-ENSAT guidelines on the management of adrenocortical carcinoma (ACC) suggest adjuvant mitotane for patients at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in ACC patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane (MIT) or observation (OBS). The primary endpoint of the study was RFS. Patients who refused randomization were offered inclusion in the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in the ADIUVO study. A total of 91 patients were enrolled in ADIUVO, 45 in the MIT and 46 in the OBS arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with MIT and OBS groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohorts could be analyzed in parallel to those of ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. Tumor size was a predictor of RFS in multivariable analysis. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55–3.32, p=0.54) and HR for death 2.171 (95%CI, 0.52–12.12, p=0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed the findings of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-year RFS is about 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care.
The pericentriolar lattice of PtK2 cells exhibits temperature and calcium modulated behavior
Nemeth, Edward F. , Salisbury, Jeffrey L., Baron, Andre T. , Suman, Vera J.

Mayo Clinic

Journal of Cell Science | April 25, 2021 | Volume: 107 | Issue: 11 | Pages: 2993-3003

10.1242/jcs.107.11.2993 | PMID 7698999 Get It

ABSTRACT In this study, we demonstrate that manipulations of temperature and free calcium alter the morphology of the centrin-containing pericentriolar lattice of PtK2 cells. Immunofluorescence microscopy reveals that low-temperature incubation (4°C) causes anti-centrin-labeled pericentrosomal spots to coalesce in the peripheral cytoplasm, and fuses small spots into larger spots near the cell center. At electron microscopic resolution, well-formed pericentriolar satellites appear around the centrioles in response to incubation at 4°C. Elevated free calcium enhances these low-temperature-dependent effects. The data suggest that peri-centrosomal spots correspond to one or more pericentriolar satellites, and that pericentriolar satellites and centrosomal matrix are interconvertable forms of the same material. Transient elevation of intracellular free calcium at 37°C from a basal level of 3.7×10−8 M to a peak level of 2.0×10−7 M within 30 seconds with ionomycin results in a 35% increase in pericentrosomal spot number throughout the cytoplasm. The number of pericentrosomal spots is 50% larger 2 minutes after ionomycin addition; these spots are also nearer to the cell center as compared to 30 seconds after ionomycin addition. As intracellular free calcium returns to a basal level over 5 minutes, the number of spots and their cellular distribution resume a pretreatment value and pattern. We interpret these observations to indicate movement of pericentrosomal spots toward the cell center in response to the flux in intracellular free calcium. Alternatively, it is possible that no movement has occurred, but that the rise in free calcium has unmasked an epitope responsive to our anti-centrin antiserum. Regardless of the interpretation, we conclude that the pericentriolar lattice exhibits calcium-modulated behavior.
Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease
Zheng, Tenghao , Ellinghaus, David , Juzėnas, Simonas , Cossais, François , Burmeister, Greta , Mayr, Gabriele , Jørgensen, Isabella Friis , Teder‐Laving, Maris , Skogholt, Anne Heidi , Chen, Sisi , Strege, Peter R. , Ito, Go , Banasik, Karina , Bokelmann, Frank, Buch, Stephan , Clausnitzer, Hartmut, Degenhardt, Frauke , Doniec, Marek J., Erikstrup, Christian , Förster, Michael , Frey, Norbert , Fritsche, Lars G. , Gabrielsen, Maiken E. , Gräßle, Tobias , Gsur, Andrea , Hampe, Jochen , Hendricks, Alexander , Hinz, Sebastian , Jongen, Johannes , Junker, Ralf, Karlsen, Tom H. , Hemmrich‐Stanisak, Georg , Kruis, Wolfgang , Kupčinskas, Juozas , Laubert, Tilman , Rosenstiel, Philip , Röcken, Christoph , Laudes, Matthias , Leendertz, Fabian H. , Limperger, Verena , Margetis, Nikolaos, Mätz‐Rensing, Kerstin, Németh, Christopher Georg , Ness‐Jensen, Eivind , Nowak‐Göttl, Ulrike, Pandit, Anita , Pedersen, Ole Birger , Peleikis, H.-G., Peuker, Kenneth , Rodríguez, Cristina Leal , Schniewind, Bodo, Schulzky, Martin, Skiecevičienė, Jurgita , Tepel, Jürgen, Thomas, Laurent F. , Uellendahl-Werth, Florian , Ullum, Henrik , Vogel, Ilka, Völzke, Henry , Schönfels, Witigo von , Vanderwerff, Brett , Wilking, Julia, Wittig, Michael , Zeißig, Sebastian , Zobel, Myrko, Zawistowski, Matthew , Vacic, Vladimir, Sazonova, Olga V. , Noblin, Elizabeth S., Farrugia, Gianrico , Kahlke, Volker, Schafmayer, Clemens , D’Amato, Mauro , Datz, Christian , Forster, Michael , Gsur, Andrea , Hampe, Jochen , Röcken, Christoph , Ness-Jensen, Eivind , Rühlemann, Malte Christoph , Farrugia, Gianrico , D'Amato, Mauro , Franke, André , Ellinghaus, David , Zheng, Tenghao , Strege, Peter R , Erikstrup, Christian , Kupcinskas, Juozas , Becker, Thomas S , Brunak, Søren , Esko, Tõnu , Groß, Justus , Hveem, Kristian , Lieb, Wolfgang , Fersen, Lorenzo von , Sazonova, Olga, Beyder, Arthur , Wedel, Thilo

Mayo Clinic

Gut | April 22, 2021 | Volume: 70 | Issue: 8 | Pages: 1538-1549

10.1136/gutjnl-2020-323868 | PMID 33888516 Get It

Objective Haemorrhoidal disease (HEM) affects a large and silently suffering fraction of the population but its aetiology, including suspected genetic predisposition, is poorly understood. We report the first genome-wide association study (GWAS) meta-analysis to identify genetic risk factors for HEM to date. Design We conducted a GWAS meta-analysis of 218 920 patients with HEM and 725 213 controls of European ancestry. Using GWAS summary statistics, we performed multiple genetic correlation analyses between HEM and other traits as well as calculated HEM polygenic risk scores (PRS) and evaluated their translational potential in independent datasets. Using functional annotation of GWAS results, we identified HEM candidate genes, which differential expression and coexpression in HEM tissues were evaluated employing RNA-seq analyses. The localisation of expressed proteins at selected loci was investigated by immunohistochemistry. Results We demonstrate modest heritability and genetic correlation of HEM with several other diseases from the GI, neuroaffective and cardiovascular domains. HEM PRS validated in 180 435 individuals from independent datasets allowed the identification of those at risk and correlated with younger age of onset and recurrent surgery. We identified 102 independent HEM risk loci harbouring genes whose expression is enriched in blood vessels and GI tissues, and in pathways associated with smooth muscles, epithelial and endothelial development and morphogenesis. Network transcriptomic analyses highlighted HEM gene coexpression modules that are relevant to the development and integrity of the musculoskeletal and epidermal systems, and the organisation of the extracellular matrix. Conclusion HEM has a genetic component that predisposes to smooth muscle, epithelial and connective tissue dysfunction.
Biomechanical, histological, and molecular characterization of a new posttraumatic model of arthrofibrosis in rats
Owen, Aaron R. , Dagneaux, Louis , Limberg, Afton K. , Bettencourt, Jacob W. , Bayram, Banu , Bolon, Brad , Berry, Daniel J., Wijnen, André J. van , Berry, Daniel J. , Sanchez-Sotelo, Joaquin, van Wijnen, Andre J , Abdel, Matthew P , Berry, Daniel J , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P.

Mayo Clinic

Journal of Orthopaedic Research | April 19, 2021 | Volume: 40 | Issue: 2 | Pages: 323-337

10.1002/jor.25054 | PMID 33871082 Get It

AbstractExperimental analyses of posttraumatic knee arthrofibrosis utilize a rabbit model as a gold standard. However, a rodent model of arthrofibrosis offers many advantages including reduced cost and comparison with other models of organ fibrosis. This study aimed to characterize the biomechanical, histological, and molecular features of a novel posttraumatic model of arthrofibrosis in rats. Forty eight rats were divided into two equal groups. An immobilization procedure was performed on the right hind limbs of experimental rats. One group was immobilized for 4 weeks and the other for 8 weeks. Both groups were remobilized for 4 weeks. Limbs were studied biomechanically via assessment of torque versus degree of extension, histologically via whole knee specimen, and molecularly via gene expression of posterior capsular tissues. Significant differences were observed between experimental and control limbs at 4 N‐cm of torque in the 4‐week (knee extension: 115° ± 8° vs. 169° ± 17°, respectively; p = 0.007) and 8‐week immobilization groups (knee extension: 99° ± 12° vs. 174° ± 9°, respectively; p = 0.008). Histologically, in each group experimental limbs demonstrated increased posterior capsular thickness and total area of tissue when compared to control limbs (p < 0.05). Gene expression values evaluated in each group were comparable. This study presents a novel rat model of arthrofibrosis with severe and persistent knee contractures demonstrated biomechanically and histologically. Statement of clinical significance: Arthrofibrosis is a common complication following contemporary total knee arthroplasties. The proposed model is reproducible, cost‐effective, and can be employed for translational investigations studying the pathogenesis of arthrofibrosis and efficacy of neoadjuvant pharmacologic agents.
Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries
Pereira, Felipe Moraes Toledo , Silva, Adriano Gonçalves e , Dettino, Aldo Lourenço Abbade , Cardoso, Ana Paula Garcia , Kann, Ariel Galapo , Dzik, Carlos, Herchenhorn, Daniel , Jardim, Denis L. , Lopera, Diego , Ayadi, Mouna , Salman, Pamela, Carvalho, Ricardo Saraiva de , Cavalléro, Sandro Roberto de Araújo , Aguiar, Sergio, Souza, Vinícius Carrera , Usón, Pedro Luiz Serrano , Soares, Andrey , Kann, Ariel Galapo , Herchenhorn, Daniel , Jardim, Denis Leonardo Fontes , Lopera, Diego , Kopp, Ray Antonio Manneh , Cavallero, Sandro Roberto De Araujo , Uson Junior, Pedro Luiz Serrano, Soares, Andrey , Uson, Pedro L S , Sasse, Andre Deeke , Salman, Pamela

Mayo Clinic

JCO Global Oncology | April 15, 2021 | Volume: No volume available | Issue: 7 | Pages: 545-549

10.1200/go.20.00507 | PMID 33856892 Get It

PURPOSE To present a summary of the recommendations for the treatment and follow-up for the biochemical recurrence of castration-resistant prostate cancer (PCa) as acquired through a questionnaire administered at the Prostate Cancer Consensus Conference for Developing Countries. METHODS A total of 27 questions were identified as relating to this topic. Responses from the clinician were tallied and are presented in percentage format. Topics included the use of imaging in staging, treatment recommendations across different patient scenarios of life expectancy and prostate-specific antigen (PSA) doubling time, and follow-up for nonmetastatic castration-resistant PCa. RESULTS A consensus agreed that in optimal conditions, positron emission tomography-computed tomography with prostate-specific membrane antigen would be used although in limited resource situations the combined use of CT of the abdomen and pelvic (or pelvic MRI), a bone scan, and a CT of the thorax or chest x-ray was recommended. In cases when PSA levels double in < 10 months, more than 90% of clinicians agreed on the use of apalutamide or enzalutamide, regardless of life expectancy. With a doubling time of more than 10 months, > 54% of experts recommended no treatment independent of life expectancy. More than half of the experts, regardless of resources, recommended follow-up with a physical examination and PSA levels every 3-6 months and imaging only in the case of symptoms. CONCLUSION The voting results and recommendations presented in this document can be used by physicians to support management for biochemical recurrence of castration-resistant PCa in areas of limited resources. Individual clinical decision making should be supported by available data.
Diabetic Kidney Disease Alters the Transcriptome and Function of Human Adipose-Derived Mesenchymal Stromal Cells but Maintains Immunomodulatory and Paracrine Activities Important for Renal Repair
Hickson, LaTonya J. , Eirin, Alfonso , Conley, Sabena M., Taner, Timucin, Bian, Xiaohui , Saad, Ahmed , Mehta, Ramila A. , McKenzie, Travis J. , Kellogg, Todd A., Kirkland, James L. , Saadiq, Ishran M. , Jordan, Kyra L., Zhu, Xiangyang , Griffin, Matthew D. , Wijnen, André J. van , Textor, Stephen C., Lerman, Lilach O. , van Wijnen, Andre J , Griffin, Matthew D , Hickson, LaTonya J , Eirin, Alfonso , Herrmann, Sandra M. , Tchkonia, Tamar , Tang, Hui Jun , Rule, Andrew D.

Mayo Clinic

Diabetes | April 15, 2021 | Volume: 70 | Issue: 7 | Pages: 1561-1574

10.2337/db19-1268 | PMID 33858824 Get It

Mesenchymal stem/stromal cells (MSCs) facilitate repair in experimental diabetic kidney disease (DKD). However, the hyperglycemic and uremic milieu may diminish regenerative capacity of patient-derived therapy. We hypothesized that DKD reduces human MSC paracrine function. Adipose-derived MSC from 38 participants with DKD and 16 control subjects were assessed for cell surface markers, trilineage differentiation, RNA sequencing (RNA-seq), in vitro function (coculture or conditioned medium experiments with T cells and human kidney cells [HK-2]), secretome profile, and cellular senescence abundance. The direction of association between MSC function and patient characteristics were also tested. RNA-seq analysis identified 353 differentially expressed genes and downregulation of several immunomodulatory genes/pathways in DKD-MSC versus Control-MSC. DKD-MSC phenotype, differentiation, and tube formation capacity were preserved, but migration was reduced. DKD-MSC with and without interferon-γ priming inhibited T-cell proliferation greater than Control-MSC. DKD-MSC medium contained higher levels of anti-inflammatory cytokines (indoleamine 2,3-deoxygenase 1 and prostaglandin-E2) and prorepair factors (hepatocyte growth factor and stromal cell–derived factor 1) but lower IL-6 versus control-MSC medium. DKD-MSC medium protected high glucose plus transforming growth factor-β–exposed HK-2 cells by reducing apoptotic, fibrotic, and inflammatory marker expression. Few DKD-MSC functions were affected by patient characteristics, including age, sex, BMI, hemoglobin A1c, kidney function, and urine albumin excretion. However, senescence-associated β-galactosidase activity was lower in DKD-MSC from participants on metformin therapy. Therefore, while DKD altered the transcriptome and migratory function of culture-expanded MSCs, DKD-MSC functionality, trophic factor secretion, and immunomodulatory activities contributing to repair remained intact. These observations support testing of patient-derived MSC therapy and may inform preconditioning regimens in DKD clinical trials.